Elderly patients with Ph+ chronic myelogenous leukemia (CML): Results of imatinib mesylate treatment

Latagliata Roberto, Breccia Massimo, Carmosino Ida, Sarlo Chiara, Montefusco Enrico, Mancini Marco, Chistolini Antonio, De Cuia Rosa, Russo Eleonora, Morano Salvatore Giacomo, Biondo Francesca, Spadea Antonio, Mandelli Franco, Alimena Giuliana, Natalino Fiammetta

Research output: Contribution to journalArticlepeer-review


Thirty-five patients with Ph+ CML aged more than 60 years were treated with imatinib. Twenty-four patients (group A) were in late chronic phase (CP) and eleven patients (group B) were in accelerated/blastic phase (AP/BP). In group A, complete haematological response (CHR) was achieved by all patients; seventeen patients (70.8%) attained a complete cytogenetic response (CCR), one (4.1%) attained a partial CR, one (4.1%) a minor CR (Ph+ 70%) and five (21%) were resistant (Ph+ 100%), toxicity was mild: seven patients had a transient cytopenia, three a skin reaction, one a moderate oedema and one muscular pain. After a median follow-up of 15 months, 1 patient died in progression and 23 patients are alive (2 in BP and 21 in persisting response). In group B, one patient died after 3 months in aplastic phase from sepsis, three patients were resistant and seven patients (63.7%) achieved CHR; of these, four obtained CCR. After a median follow-up of 17 months, 4 patients have died from progressive disease, 6 are alive; 1 in AP and 5 in CHR (4 of them being in CCR). Present data indicate that imatinib is safe also in elderly with clinical results as good as in younger patients.

Original languageEnglish
Pages (from-to)287-291
Number of pages5
JournalLeukemia Research
Issue number3
Publication statusPublished - Mar 2005


  • CML
  • Elderly
  • Imatinib

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Elderly patients with Ph+ chronic myelogenous leukemia (CML): Results of imatinib mesylate treatment'. Together they form a unique fingerprint.

Cite this